NFE2L2 and pancreatic neoplasm: In a recently published study, Dai et al. identified the compound NSC84167 (7-oxo-7H-benzo[e]perimidine-4-carboxylic acid), selectively targeting Nrf2-activated pancreatic cancers by inhibiting the asparagine synthesis pathway [60].